Gujarat Themis Biosyn raises ₹335 crore via 2026 issue

What the board approved on September 1, 2026

Gujarat Themis Biosyn Ltd informed the BSE about the outcome of its board meeting held on September 1, 2026. The company’s board approved a preferential allotment of 82.11 lakh equity shares. The issue price was set at ₹408 per share. Based on the stated price and quantity, the proposed raise aggregates to ₹335 crore. The fundraising is structured as a private placement to a set of identified investors. The company indicated that the transaction is subject to shareholder and stock exchange approvals before it can be finalised. The board meeting outcome was time-stamped at 5:00 pm, with the source cited as BSE.

Preferential allotment: size, price, and structure

The preferential issue approved by the board is for 82.11 lakh equity shares at ₹408 each. The company disclosed the overall amount as ₹335 crore. The proposal involves five proposed allottees, indicating a targeted placement rather than a broad-based public issue. The article notes that the board meeting scheduled for September 1, 2026 was convened to consider fund raising. It also noted that the proposal included equity shares and convertible warrants via private placement, with shareholder approval and regulatory clearances required. While the board approval marks a key milestone, the stated approvals are necessary steps before allotment can be completed.

Who the proposed allottees are

Among the proposed allottees, Pharmaceutical Business Group (India) Limited, a promoter group entity, was identified as the largest recipient. The amount attributed to this promoter group entity was ₹250 crore. The disclosure also mentioned four non-promoter investors, including Special Situation India Fund and ISAF III Onshore Fund. The names of the remaining non-promoter investors were not fully detailed in the provided text. The overall structure, as described, mixes promoter participation with non-promoter institutional capital. Any change in shareholding and promoter stake would ultimately depend on the final allotment and completion of the approval process.

QIP committee outcome referenced on August 28, 2026

Separately, the provided text references an “Outcome of the Fund Raising Committee held on 28.08.2026 for allotment of equity shares through QIP.” It also notes that Gujarat Themis Biosyn approved the closure of the QIP issue period on August 28, 2026. The presence of both a QIP-related committee outcome and a preferential issue board approval in the same period signals that the company has been active on capital raising routes. However, the provided excerpt does not specify the QIP issue size or the number of shares allotted under the QIP route. As a result, the quantifiable fundraising information in this item remains centered on the preferential allotment amount and pricing.

EGM and shareholder processes around August 2026

The material also points to shareholder actions during August 2026. Gujarat Themis Biosyn held an Extraordinary General Meeting (EGM) on August 22, 2026 in Vapi, Gujarat. The Punjabi-language excerpt states that shareholders approved three key proposals with the required majority. These included significant related-party transactions with promoter entities, amendments to the Articles of Association (AOA), and private placement of non-convertible debentures (NCDs) and or other debt securities. Remote e-voting for the EGM was available from August 19 to August 21, 2026, with an additional option for voting via ballot paper at the venue. The text notes that, with these resolutions passed, the company can proceed to implement the approved related-party transactions, finalise terms for private placement of debt instruments, and formally implement AOA changes.

Postal ballot voting: key dates and results cited

The company also published a notice regarding an upcoming postal ballot, inviting shareholders to approve key proposals via remote e-voting. The remote e-voting window was scheduled from July 24, 2026 through August 22, 2026. Shareholders as of the cut-off date of July 10, 2026 were stated to be eligible to vote. The results were expected to be announced by August 25, 2026. The excerpt includes voting outcome statistics: total votes polled were 79,496,307, with votes in favor at 79,477,366, representing 99.9762%. While the precise resolutions for the postal ballot are not fully enumerated in the excerpt, the timeline and vote figures indicate strong shareholder support for the matter(s) put to vote.

Business snapshot and company identifiers

Gujarat Themis Biosyn Ltd manufactures and markets bulk drugs and intermediates, specialising in anti-tuberculosis and antibiotic products. It focuses on fermentation-based APIs and caters to domestic and international pharmaceutical markets. The company’s listed address in the excerpt is Plot No. 69-C, G.I.D.C. Industrial Estate, Vapi, Valsad District, Gujarat, 396195. The email contact shown is cfoassist@themismedicare.com and the website is http://www.gtbl.in. The excerpt also references the company code 506879. Named members of management in the provided material include Dinesh S Patel (Non Executive Chairman) and Sachin D Patel (Managing Director), along with independent directors Hitesh D Gajaria, K G Ananthakrishnan, and Nihar Parikh.

Board meeting cadence: results and corporate actions

The company’s board calendar in the provided text includes multiple events. A board meeting dated August 7, 2026 is referenced for quarterly results, and another listing shows “Aug 6, 2026” announced on July 30, 2026 for a board meeting for quarterly results. The text also mentions a board meeting scheduled for February 5, 2026 to review and approve unaudited financial results for the third quarter and the first nine months of FY 2025-26 ending December 31, 2025. Another board meeting was scheduled on November 10, 2025 to approve unaudited financial results for Q2 and H1 FY26, covering the period ending September 30, 2025. In addition, the company held its 44th AGM on September 12, 2025, where all ten resolutions including adoption of financial statements and dividend declaration received shareholder approval.

Key facts table

Market impact: what changes and what remains pending

From a market perspective, the immediate, confirmed development is the board’s approval of the preferential allotment terms. The disclosed price, quantity, and total amount provide clarity on the fundraising scale. But the company explicitly noted that shareholder and stock exchange approvals are required before finalisation, meaning the capital raise is not yet complete at the approval stage described. The promoter group participation of ₹250 crore is a notable component within the ₹335 crore proposal, and investors typically track how such participation aligns with governance processes and final allotment conditions. The presence of institutional non-promoter investors, as named, suggests demand from external capital pools, but the excerpt does not provide their allocation quantities. Separately, the references to QIP committee actions and QIP issue period closure show concurrent capital-market activity, though the numerical details of that QIP route are not specified in the provided text.

Why this matters for shareholders and governance tracking

The sequence of board and shareholder events in August and September 2026 indicates that Gujarat Themis Biosyn has been running multiple corporate processes in parallel, including equity fundraising, debt-related approvals, and governance changes. The EGM approvals around related-party transactions and AOA amendments are relevant context because they expand the set of corporate actions shareholders may monitor during a fundraising cycle. The postal ballot timeline and the high percentage of votes in favor, as cited, show broad shareholder support for the item(s) voted on in that process. For investors, the near-term focus typically shifts to the completion steps expressly mentioned in the disclosure, including shareholder approval where applicable and stock exchange approvals. Any further outcome updates would be expected through subsequent BSE filings tied to allotment completion and regulatory clearances.

Conclusion

Gujarat Themis Biosyn’s board approval for a preferential allotment of 82.11 lakh shares at ₹408 per share sets up a proposed ₹335 crore capital raise, with a ₹250 crore allocation indicated for a promoter group entity. The company has also referenced QIP-related committee outcomes dated August 28, 2026 and an EGM held on August 22, 2026 that cleared key proposals. The next steps, as stated in the disclosure, are shareholder and stock exchange approvals before the preferential issue can be finalised. Investors will likely watch for follow-up filings that confirm approvals and detail the final allotment to the five proposed allottees.